In recent years, a new AKI biomarker system, a composite of the two independent proteins metalloproteinase inhibitor 2 (TIMP2) and the IGF-binding protein 7 (IGFBP7), in urine samples has been introduced and has been widely accepted on the basis of a large number of clinical trials [9,22,23]. This evidence concerns the gene TIMP2 and acute kidney injury.